Brokers Offer Predictions for Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Equities researchers at Brookline Capital Management upped their FY2025 earnings per share estimates for shares of Kura Oncology in a research note issued to investors on Thursday, November 21st. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($1.74) per share for the year, up from their previous estimate of ($2.27). The consensus estimate for Kura Oncology's current full-year earnings is ($2.42) per share. Brookline Capital Management also issued estimates for Kura Oncology's FY2026 earnings at $0.95 EPS, FY2027 earnings at $3.16 EPS and FY2028 earnings at $5.97 EPS.

Other equities research analysts have also recently issued research reports about the company. Stifel Nicolaus cut Kura Oncology from a "buy" rating to a "hold" rating and cut their target price for the company from $26.00 to $19.00 in a research note on Monday, October 14th. Bank of America lowered their price target on Kura Oncology from $36.00 to $29.00 and set a "buy" rating on the stock in a research report on Friday. StockNews.com lowered Kura Oncology from a "hold" rating to a "sell" rating in a research report on Wednesday, November 20th. Jefferies Financial Group lowered their price target on Kura Oncology from $32.00 to $28.00 and set a "buy" rating on the stock in a research report on Thursday. Finally, UBS Group initiated coverage on Kura Oncology in a research report on Thursday, October 24th. They set a "buy" rating and a $27.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $29.38.

Kura Oncology Stock Up 0.9 %

NASDAQ KURA traded up $0.10 during trading on Monday, hitting $10.90. The stock had a trading volume of 2,512,579 shares, compared to its average volume of 1,000,675. The company has a market capitalization of $847.58 million, a PE ratio of -4.68 and a beta of 0.86. The company's 50-day moving average price is $17.88 and its two-hundred day moving average price is $19.67. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a 12 month low of $9.06 and a 12 month high of $24.17.

Institutional Trading of Kura Oncology

Several institutional investors have recently added to or reduced their stakes in the company. Suvretta Capital Management LLC boosted its stake in Kura Oncology by 8.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock valued at $149,535,000 after purchasing an additional 583,155 shares during the period. Vanguard Group Inc. lifted its position in shares of Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company's stock valued at $86,726,000 after acquiring an additional 28,212 shares during the period. Armistice Capital LLC lifted its position in shares of Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company's stock valued at $48,386,000 after acquiring an additional 302,000 shares during the period. Artal Group S.A. lifted its position in shares of Kura Oncology by 8.6% during the 1st quarter. Artal Group S.A. now owns 1,919,884 shares of the company's stock valued at $40,951,000 after acquiring an additional 151,828 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Kura Oncology by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock valued at $34,798,000 after acquiring an additional 41,535 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.